2.21
price down icon5.96%   -0.14
pre-market  Vorhandelsmarkt:  2.21  
loading

Nrx Pharmaceuticals Inc Aktie (NRXP) Neueste Nachrichten

pulisher
Dec 09, 2025

NRx Eyes Faster Commercial Path as NRX-101 Moves Into TMS-Enhanced Depression Treatment - MyChesCo

Dec 09, 2025
pulisher
Dec 08, 2025

NRx’s Preservative-Free Ketamine Reaches FDA Review as Company Targets 2026 Launch - MyChesCo

Dec 08, 2025
pulisher
Dec 08, 2025

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Dec 08, 2025
pulisher
Dec 05, 2025

Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NRXP), Akebia Therapeutics (AKBA) and Ionis Pharmaceuticals (IONS) - The Globe and Mail

Dec 05, 2025
pulisher
Dec 04, 2025

Cash from financing activities of NRX Pharmaceuticals, Inc. – HAM:B1Q - TradingView

Dec 04, 2025
pulisher
Dec 04, 2025

Is NRx Pharmaceuticals Inc. stock a bargain at current levelsMarket Rally & Weekly Top Stock Performers List - Newser

Dec 04, 2025
pulisher
Dec 04, 2025

BTIG Research Reiterates Buy Rating for NRx Pharmaceuticals (NASDAQ:NRXP) - MarketBeat

Dec 04, 2025
pulisher
Dec 04, 2025

NRx Pharmaceuticals amends IND filing for NRX-101 to include use for TMS - MSN

Dec 04, 2025
pulisher
Dec 04, 2025

Is NRx Pharmaceuticals Inc. Equity Warrant stock cheap compared to fundamentalsMarket Weekly Review & Verified Chart Pattern Trade Signals - Newser

Dec 04, 2025
pulisher
Dec 03, 2025

NRXP Analyst Maintains Buy Rating with $34 Target | NRXP Stock N - GuruFocus

Dec 03, 2025
pulisher
Dec 03, 2025

NRx Pharmaceuticals (NRXP) Amends IND to Advance NRX-101 With TMS for Depression Treatment - NewMediaWire

Dec 03, 2025
pulisher
Dec 03, 2025

NRx Pharmaceuticals (NASDAQ: NRXP) Amends IND to Advance NRX-101 With TMS for Depression Treatment - Digital Journal

Dec 03, 2025
pulisher
Dec 03, 2025

NRx Pharmaceuticals' (NRXP) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat

Dec 03, 2025
pulisher
Dec 03, 2025

More Than 1 Million Suicidal Depression Cases Per Year May Be Treated by 2030 via New Indication for Augmentation of Transcranial Magnetic Stimulation: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - The Globe and Mail

Dec 03, 2025
pulisher
Dec 03, 2025

NRx Pharmaceuticals to Discuss New NRX-101 Pipeline Indication for Augmentation of Transcranial Magnetic Stimulation - citybiz

Dec 03, 2025
pulisher
Dec 03, 2025

Nrx Pharmaceuticals Inc amends IND filing for NRX-101 to include TMS use - marketscreener.com

Dec 03, 2025
pulisher
Dec 03, 2025

NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation - Investing News Network

Dec 03, 2025
pulisher
Dec 03, 2025

NRx Pharmaceuticals Amends Investigational New Drug Filing for NRX-101 to Include Use with Transcranial Magnetic Stimulation in Treatment of Depression - Quiver Quantitative

Dec 03, 2025
pulisher
Dec 03, 2025

BTIG Reiterates NRx Pharmaceuticals (NRXP) Buy Recommendation - Nasdaq

Dec 03, 2025
pulisher
Dec 03, 2025

NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial ... - Enidnews.com

Dec 03, 2025
pulisher
Dec 03, 2025

NRx Pharmaceuticals to discuss new NRX-101 pipeline - GlobeNewswire

Dec 03, 2025
pulisher
Dec 02, 2025

D. Boral Capital Maintains NRx Pharmaceuticals (NRXP) Buy Recommendation - Nasdaq

Dec 02, 2025
pulisher
Dec 02, 2025

Market Wrap: What momentum indicators show for NRx Pharmaceuticals Inc. stock2025 Valuation Update & Precise Trade Entry Recommendations - BỘ NỘI VỤ

Dec 02, 2025
pulisher
Dec 02, 2025

NRx Pharmaceuticals (NASDAQ: NRXP) Announces FDA Receipt of ANDA for KETAFREE With July 2026 Review Goal Date - Digital Journal

Dec 02, 2025
pulisher
Dec 02, 2025

NRx Pharmaceuticals (NRXP) Announces FDA Receipt of ANDA for KETAFREE With July 2026 Review Goal Date - NewMediaWire

Dec 02, 2025
pulisher
Dec 02, 2025

NRXP: Analyst Maintains 'Buy' Rating with $34 Target Price | NRX - GuruFocus

Dec 02, 2025
pulisher
Dec 02, 2025

FDA Submission for Abbreviated New Drug Application; $750 - openPR.com

Dec 02, 2025
pulisher
Dec 02, 2025

NRx Pharmaceuticals Announces US Food and Drug Administration Receipt of ANDA for KETAFREE, a Preservative-Free IV KetamineNRx Pharmaceuticals - citybiz

Dec 02, 2025
pulisher
Dec 02, 2025

NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine - The Manila Times

Dec 02, 2025
pulisher
Dec 02, 2025

Nrx Pharmaceuticals announces US Food and Drug Administration (FDA) receipt of ANDA for Ketafree - marketscreener.com

Dec 02, 2025
pulisher
Dec 02, 2025

Nrx Pharmaceuticals Announces Us Food And Drug Administration (FDA) Receipt Of ANDA For Ketafree - TradingView

Dec 02, 2025
pulisher
Dec 02, 2025

NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call - The Manila Times

Dec 02, 2025
pulisher
Dec 02, 2025

NRx Pharmaceuticals (NASDAQ: NRXP) plans Dec. 2, 9:00am ET corporate update call - Stock Titan

Dec 02, 2025
pulisher
Dec 02, 2025

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Dec 02, 2025
pulisher
Dec 01, 2025

After-Hours Spotlight: Jasper, NRx, Unicycive, Spruce, Evaxion, Solana, Protara Gain Post-Close - Nasdaq

Dec 01, 2025
pulisher
Dec 01, 2025

NRx Pharmaceuticals (NASDAQ: NRXP) to Present at NobleCon21 - MSN

Dec 01, 2025
pulisher
Dec 01, 2025

NRx Pharmaceuticals (NRXP) to Present at NobleCon21 - NewMediaWire

Dec 01, 2025
pulisher
Dec 01, 2025

NRx Pharmaceuticals and HOPE Therapeutics to Present at NobleCon21Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference - citybiz

Dec 01, 2025
pulisher
Dec 01, 2025

NRx Pharmaceuticals to Present at NobleCon21 on Advances in Psychiatric Treatments and Drug Development - Quiver Quantitative

Dec 01, 2025
pulisher
Dec 01, 2025

NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference - marketscreener.com

Dec 01, 2025
pulisher
Dec 01, 2025

NRx Pharmaceuticals (NASDAQ: NRXP) to outline revenue and pipeline progress at NobleCon21 - Stock Titan

Dec 01, 2025
pulisher
Nov 30, 2025

What Macro Trends Could Affect Ruchira Papers Limiteds OutlookStock Valuation Metrics & Free Discover Breakout Stocks Early - earlytimes.in

Nov 30, 2025
pulisher
Nov 27, 2025

Is NRx Pharmaceuticals Inc. stock a buy in volatile marketsMarket Activity Summary & Reliable Price Breakout Alerts - BỘ NỘI VỤ

Nov 27, 2025
pulisher
Nov 27, 2025

NRx Pushes Fast-Track Depression Treatments as Losses Mount and Clinics Expand - MSN

Nov 27, 2025
pulisher
Nov 27, 2025

Why NRx Pharmaceuticals Inc. Equity Warrant stock attracts global investorsWeekly Trade Report & Expert Curated Trade Setup Alerts - moha.gov.vn

Nov 27, 2025
pulisher
Nov 27, 2025

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Receipt of Final Clearance to Proceed to Closing of Dura Medical Acquisition from Florida's Agency for Health Care Administration (AHCA) (PR Newswire) - Aktiellt

Nov 27, 2025
pulisher
Nov 26, 2025

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of a Citizen Petition with the US Food and Drug Administration Seeking Removal of Benzethonium Chloride from Ketamine Products (PR Newswire) - Aktiellt

Nov 26, 2025
pulisher
Nov 26, 2025

NRx Pharmaceuticals appoints Weinberg as new auditor, dismisses Salberg By Investing.com - Investing.com Canada

Nov 26, 2025
pulisher
Nov 26, 2025

NRx Pharmaceuticals appoints Weinberg as new auditor, dismisses Salberg - Investing.com

Nov 26, 2025
pulisher
Nov 26, 2025

[8-K] NRX Pharmaceuticals, Inc. Reports Material Event | NRXP SEC FilingForm 8-K - Stock Titan

Nov 26, 2025
pulisher
Nov 26, 2025

Will NRx Pharmaceuticals Inc. stock pay special dividendsMarket Performance Recap & Technical Pattern Alert System - BỘ NỘI VỤ

Nov 26, 2025
pulisher
Nov 26, 2025

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Join Fireside Chat at BTIG Virtual Biotech Conference July 2930, 2025 (PR Newswire) - Aktiellt

Nov 26, 2025
pulisher
Nov 25, 2025

Shakti Pumps Reports on Physical Share Transfer Requests - The Globe and Mail

Nov 25, 2025
$38.26
price up icon 0.45%
$95.17
price up icon 0.01%
$31.24
price up icon 1.00%
$95.73
price down icon 0.12%
biotechnology ONC
$322.68
price up icon 1.25%
$189.85
price down icon 2.22%
Kapitalisierung:     |  Volumen (24h):